This pharmaceutical company has seen 2 positive estimate revisions in the last 60 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
Durata Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Investors interested in the Med-Drugs industry may also consider stocks like Endo International plc (ENDP), Endocyte, Inc. (ECYT) and Salix Pharmaceuticals Ltd. (SLXP). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment